{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T12:39:32Z","timestamp":1752669572327},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2007,7,5]],"date-time":"2007-07-05T00:00:00Z","timestamp":1183593600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z. Rheumatol."],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1007\/s00393-007-0186-0","type":"journal-article","created":{"date-parts":[[2007,7,3]],"date-time":"2007-07-03T09:41:01Z","timestamp":1183455661000},"page":"533-535","source":"Crossref","is-referenced-by-count":12,"title":["Nephrogene systemische Fibrose"],"prefix":"10.1007","volume":"66","author":[{"given":"B.","family":"Manger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,7,5]]},"reference":[{"key":"186_CR1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jaad.2006.10.048","volume":"56","author":"Boyd","year":"2007","unstructured":"Boyd AS, Zic JA, Abraham JL (2007) Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 56: 27\u201330","journal-title":"J Am Acad Dermatol"},{"key":"186_CR2","first-page":"586","volume":"188","author":"Broome","year":"2007","unstructured":"Broome DR, Girguis MS, Baron PW et al. (2007) Gadodiamide-associated nephrogenic systemic fibrosis: Why radiologists should be concerned. Am J Radiol 188: 586\u2013592","journal-title":"Am J Radiol"},{"key":"186_CR3","first-page":"137","volume":"56","author":"Centers","year":"2007","unstructured":"Centers for Disease Control and Prevention (2007) Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents \u2013 St. Louis, Missouri, 2002\u20132006. MMWR Morb Mortal Wkly Rep 56: 137\u2013141","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"186_CR4","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jvir.2007.01.025","volume":"18","author":"Chewning","year":"2007","unstructured":"Chewning RH, Murphy KJ (2007) Gadolinium-based contrast media and the development of nephrogenic systemic fibrosis in patients with real insufficiency. J Vasc Interv Radiol 18: 331\u2013334","journal-title":"J Vasc Interv Radiol"},{"key":"186_CR5","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.semarthrit.2005.09.005","volume":"35","author":"Cowper","year":"2006","unstructured":"Cowper SE, Bucala R, Leboit PE (2006) Nephrogenic fibrosing dermopathy\/nephrogenic systemic fibrosis \u2013 Setting the record straight. Semin Arthritis Rheum 35: 208\u2013210","journal-title":"Semin Arthritis Rheum"},{"key":"186_CR6","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(00)02694-5","volume":"356","author":"Cowper","year":"2000","unstructured":"Cowper SE, Robin HS, Steinberg SM et al. (2000) Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 356: 1000\u20131001","journal-title":"Lancet"},{"key":"186_CR7","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/00000372-200110000-00001","volume":"23","author":"Cowper","year":"2001","unstructured":"Cowper SE, LD Su, Bhawan J et al. (2001) Nephrogenic fibrosing dermopathy. Am J Dermatopathol 23: 383\u2013393","journal-title":"Am J Dermatopathol"},{"key":"186_CR8","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1097\/00002281-200311000-00017","volume":"15","author":"Cowper","year":"2003","unstructured":"Cowper SE (2003) Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol 15: 785\u2013790","journal-title":"Curr Opin Rheumatol"},{"key":"186_CR9","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1001\/archderm.140.11.1401","volume":"140","author":"Fazeli","year":"2004","unstructured":"Fazeli A, Lio PA, Liu V (2004) Nephrogenic fibrosing dermopathy: are ACE inhibitors the missing link? Arch Dermatol 140: 1401","journal-title":"Arch Dermatol"},{"key":"186_CR10","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1097\/01.bor.0000245725.94887.8d","volume":"18","author":"Galan","year":"2006","unstructured":"Galan A, Cowper SE, Bucala R (2006) Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). Curr Opin Rheum 18: 614\u2013617","journal-title":"Curr Opin Rheum"},{"key":"186_CR11","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1093\/ndt\/gfk062","volume":"21","author":"Grobner","year":"2006","unstructured":"Grobner T (2006) Gadolinium \u2013 a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21: 1104\u20131108","journal-title":"Nephrol Dial Transplant"},{"key":"186_CR12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jaad.2006.10.047","volume":"56","author":"High","year":"2007","unstructured":"High WA, Ayers RA, Chandler J et al. (2007) Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56: 21\u201326","journal-title":"J Am Acad Dermatol"},{"key":"186_CR13","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.jaad.2007.01.022","volume":"56","author":"High","year":"2007","unstructured":"High WA, Eng M, Ayers RA, Cowper SE (2007) Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56: 710\u2013712","journal-title":"J Am Acad Dermatol"},{"key":"186_CR14","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1002\/art.20362","volume":"50","author":"Jimenez","year":"2004","unstructured":"Jimenez SA, Artlett CM, Sandorfi N et al. (2004) Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy). Arthritis Rheum 50: 2660\u20132666","journal-title":"Arthritis Rheum"},{"key":"186_CR15","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/01.rli.0000253505.88945.d5","volume":"42","author":"Khurana","year":"2007","unstructured":"Khurana A, Runge VM, Narayanan M et al. (2007) Nephrogenic systemic fibrosis. A review of 6 cases temporally related to gadodiamide injection (Omniscan). Invest Radiol 42: 139\u2013145","journal-title":"Invest Radiol"},{"key":"186_CR16","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1148\/radiol.2423061640","volume":"242","author":"Kuo","year":"2007","unstructured":"Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE (2007) Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology 242: 647\u2013649","journal-title":"Radiology"},{"key":"186_CR17","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1001\/archderm.139.7.928","volume":"139","author":"LeBoit","year":"2003","unstructured":"LeBoit PE (2003) What nephrogenic fibrosing dermopathy might be. Arch Dermatol 139: 928\u2013930","journal-title":"Arch Dermatol"},{"key":"186_CR18","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1067\/mjd.2003.78","volume":"38","author":"Mackay-Wiggan","year":"2003","unstructured":"Mackay-Wiggan JM, Cohen DJ, Hardy MA et al. (2003) Nephrogenic fibrosing dermophathy (scleromyxedema-like illness of renal disease). J Am Acad Dermatol 38: 55\u201360","journal-title":"J Am Acad Dermatol"},{"key":"186_CR19","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1111\/j.1600-6143.2006.01420.x","volume":"6","author":"Maloo","year":"2006","unstructured":"Maloo M, Abt P, Kashyap et al. (2006) Nephrogenic systemic fibrosis among liver transplant recipients: A single institution experience and topic update. Am J Transplant 6: 2212\u20132217","journal-title":"Am J Transplant"},{"key":"186_CR20","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1681\/ASN.2006060601","volume":"17","author":"Marckmann","year":"2006","unstructured":"Marckmann P, Skov L, Rossen K et al. (2006) Nephrogenic systemic fibrosis: Suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17: 2359\u20132362","journal-title":"J Am Soc Nephrol"},{"key":"186_CR21","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.semarthrit.2005.08.002","volume":"35","author":"Mendoza","year":"2006","unstructured":"Mendoza FA, Artlett CM, Sandorfi N et al. (2006) Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum 35: 238\u2013249","journal-title":"Semin Arthritis Rheum"},{"key":"186_CR22","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1259\/bjr\/17111243","volume":"80","author":"Morcos","year":"2007","unstructured":"Morcos SK (2007) Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? Br J Radiol 80: 73\u201376","journal-title":"Br J Radiol"},{"key":"186_CR23","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1191\/0961203304lu1069cr","volume":"13","author":"Obermoser","year":"2004","unstructured":"Obermoser G, Emberger M, Wieser M et al. (2004) Nephrogenic fibrosing dermopathy in two patients with systemic lupus erythematosus. Lupus 13: 609\u2013612","journal-title":"Lupus"},{"key":"186_CR24","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1148\/radiol.2431062144","volume":"243","author":"Sadowski","year":"2007","unstructured":"Sadowski EA, Bennett LK, Chan MR et al. (2007) Nephrogenic systemic fibrosis: Risk factors and incidence estimation. Radiology 243: 148\u2013157","journal-title":"Radiology"},{"key":"186_CR25","first-page":"229","volume":"146","author":"Swaminathan","year":"2006","unstructured":"Swaminathan S, Ahmed I, McCarthy JT et al. (2006) Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann Intern Med 146: 229\u2013230","journal-title":"Ann Intern Med"},{"key":"186_CR26","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1007\/s00330-006-0495-8","volume":"16","author":"Thomsen","year":"2006","unstructured":"Thomsen HS (2006) Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide. Eur Radiol 16: 2619\u20132621","journal-title":"Eur Radiol"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-007-0186-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-007-0186-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-007-0186-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T16:29:39Z","timestamp":1559060979000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-007-0186-0"}},"subtitle":["Medizinische Detektivarbeit im 21. Jahrhundert"],"short-title":[],"issued":{"date-parts":[[2007,7,5]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["186"],"URL":"https:\/\/doi.org\/10.1007\/s00393-007-0186-0","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,7,5]]}}}